Skip to main content

OPTIMIZACION DEL POTENCIAL TERAPEUTICO DE LAS PROTEIN QUINASAS (PKS) DE LEISHMANIA. DESCUBRIMIENTO DE FARMACOS INHIBIDORES ESPECIFICOS DE LAS PKS DEL PARASITO

SAF2015-65740-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Lytic cell death induced by melittin bypasses pyroptosis but induces NLRP3 inflammasome activation and IL-1β release

  • Martín-Sánchez, Fátima
  • Martínez-García, Juan José
  • Muñoz-García, María
  • Martínez-Villanueva, Miriam
  • Noguera-Velasco, José A.
  • Andreu Martínez, David
  • Rivas, Luis
  • Pelegrín, Pablo
The nucleotide-binding domain and leucine-rich repeat-containing receptor with a pyrin domain 3 (NLRP3) inflammasome is a sensor for different types of infections and alterations of homeostatic parameters, including abnormally high levels of the extracellular nucleotide ATP or crystallization of different metabolites. All NLRP3 activators trigger a similar intracellular pathway, where a decrease in intracellular K+ concentration and permeabilization of plasma membrane are key steps. Cationic amphipathic antimicrobial peptides and peptide toxins permeabilize the plasma membrane. In fact, some of them have been described to activate the NLRP3 inflammasome. Among them, the bee venom antimicrobial toxin peptide melittin is known to elicit an inflammatory reaction via the NLRP3 inflammasome in response to bee venom. Our study found that melittin induces canonical NLRP3 inflammasome activation by plasma membrane permeabilization and a reduction in the intracellular K+ concentration. Following melittin treatment, the apoptosis-associated speck-like protein, an adaptor protein with a caspase recruitment domain (ASC), was necessary to activate caspase-1 and induce IL-1β release. However, cell death induced by melittin prevented the formation of large ASC aggregates, amplification of caspase-1 activation, IL-18 release and execution of pyroptosis. Therefore, melittin-induced activation of the NLRP3 inflammasome results in an attenuated inflammasome response that does not result in caspase-1 dependent cell death., This work was supported by SAF2015-65740-R and Subdirección General de Redes y Centros de Investigación Cooperativa-FEDER, RICET RD12/0018/0007 and RD16/0027/0010. This work was also supported by grants from the European Research Council (ERC-2013-CoG 614578 to PP) and the Instituto Salud Carlos III-Fondo Europeo de Desarrollo Regional (PI13/00174 to PP). FM-S was supported by the Sara Borrell postdoctoral grant from the Instituto Salud Carlos III (CD12/00523)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Medicinal and biological chemistry (MBC) library: an efficient source on new hits, The medicinal and biological chemistry (MBC) library: an efficient source on new hits

  • Sebastián-Pérez, Víctor
  • Roca, Carlos
  • Awale, Mahendra
  • Reymond, Jean-Louis
  • Martínez Gil, Ana
  • Gil, Carmen
  • Campillo, Nuria E.
22 p.-6 fig.-3 tab., Identification of new hits is one of the biggest challenges in drug discovery. Creating a library of well-characterized drug-like compounds is a key step in this process. Our group has developed an in-house chemical library called Medicinal and Biological Chemistry (MBC) library. This collection has been successfully used to start several medicinal chemistry programs and developed in an accumulation of more than thirty years of experience in drug design and discovery of new drugs for unmet diseases. It contains over 1,000 compounds, mainly heterocyclic scaffolds. In this work, an analysis of drug-like properties and comparative study with well-known libraries by using different computer software is here presented., Financial support from MINECO (grant no. CTQ2015-66313 and SAF2015-65740) and the EC 7th Framework Programme (FP7-HEALTH-2013-INNOVATION-1, PDE4NPD no. 602666). We also thanks to MECD (Grant of V.S, FPU15/01465)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cyclic nucleotide specific phosphodiesterases as potential drug targets for anti-Leishmania therapy, PDEs: therapeutic targets for leishmaniasis

  • Sebastián-Pérez, Víctor
  • Hendrickx, Sarah
  • Munday, Jane C.
  • Kalejaiye, Titilola
  • Martínez Gil, Ana
  • Campillo, Nuria E.
  • Koning, Harry de
  • Caljon, Guy
  • Maes, Louis
  • Gil, Carmen
The available treatments for leishmaniasis are less than optimal due to inadequate efficacy, toxic side-effects and the emergence of resistant strains, clearly endorsing the urgent need for discovery and development of novel drug candidates. Ideally, these should act via an alternative mechanism-of-action to avoid cross-resistance with the current drugs. As cyclic nucleotide specific phosphodiesterases (PDEs) of L. major have been postulated as putative drug targets, a series of potential inhibitors of Leishmania PDEs was explored. Several displayed potent and selective in vitro activity against L. infantum intracellular amastigotes. One imidazole derivative, compound 35, was shown to reduce the parasite loads in vivo and dose-dependently increase the cellular cAMP level at just 2* and 5* the IC50, indicating a correlation between antileishmanial activity and increased cellular cAMP. Docking studies and molecular dynamics simulations pointed to imidazole 35 exerting its activity through PDE inhibition. This study establishes for the first time that inhibition of cAMP PDEs can potentially be exploited for new antileishmanial chemotherapy., Funding from the EC 7th Framework Programme (FP7-HEALTH-2013 INNOVATION-1, PDE4NPD no. 602666), MINECO (Grant SAF2015-65740-R), RICET (RD16/0027/0010), FEDER funds and MECD (Grant FPU15/1465 to V. S.-P.) is acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Molecular basis of the leishmanicidal activity of the antidepressant sertraline as a drug repurposing candidate, Leishmanicidal mechanism of sertraline

  • Lima, Marta L.
  • Abengozar, M. A.
  • Nácher-Vázquez, Montserrat
  • Martinez-Alcazar, Maria P.
  • Barbas, Coral
  • Tempone, Andre G.
  • López-Gonzálvez, Ángeles
  • Rivas, Luis
42 p.-8 fig., Drug repurposing affords the implementation of new treatments at a moderate cost and under a faster time-scale. Most of the clinical drugs against Leishmania share this origin. The antidepressant sertraline has been successfully assayed in a murine model of visceral leishmaniasis. Nevertheless, sertraline targets in Leishmania were poorly defined. In order to get a detailed insight into the leishmanicidal mechanism of sertraline on Leishmania infantum, unbiased multiplatform metabolomics and transmission electron microscopy were combined with a focused insight into the sertraline effects on bioenergetics metabolism of the parasite. Sertraline induced respiration uncoupling, a significant decrease of intracellular ATP level, and oxidative stress in L. infantum promastigotes. Metabolomics evidenced an extended metabolic disarray caused by sertraline. This encompasses a remarkable variation of the levels of thiol-redox and polyamine biosynthetic intermediates, as well as shortage of intracellular amino acids used as metabolic fuel by Leishmania Sertraline killed Leishmania through a multitarget mechanism of action, tackling essential metabolic pathways of the parasite. As such, sertraline is a valuable candidate for visceral leishmaniasis treatment under a drug repurposing strategy., This work was supported by grants of the Fondo de Investigaciones Sanitarias-ISCIII-FEDER (PI12-02706), and (RD16/0027/0010, Red de Enfermedades Tropicales, subprogram RETICS del Plan Estatal de I+D+i (2013-2016) co-financed with FEDER funds, SAF2015-65740-R, and CSIC PIE 201620E038 to L. R., São Paulo State Research Foundation (FAPESP 2015/23403-9 to A. G.T.); EADS-CASA/ Brazilian Air Force (FAB) mobility program to M.L.L., and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) to M.L.L., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Cyanobacterial peptides as a tour de force in the chemical space of antiparasitic agents

  • Rivas, Luis
  • Rojas, Verónica
53 p.-4 fig.-3 tab., Parasites are scarcely addressed target for antimicrobial peptides despite their big impact in health and global economy. The notion of antimicrobial peptides is frequently associated to the innate immune defense of vertebrates and invertebrate vectors, as the ultimate recipients of the parasite infection. These antiparasite peptides are produced by ribosomal synthesis, with few post-translational modifications, and their diversity come mostly from their amino acid sequence. For many of them permeabilization of the cell membrane of the targeted pathogen is crucial for their microbicidal mechanism. In contrast, cyanobacterial peptides are produced either by ribosomal or non-ribosomal biosynthesis. Quite often, they undergo heavy modifications, such as the inclusion of non-proteinogenic amino acids, lipid acylation, cyclation, Nα-methylation, or heterocyclic rings. Furthermore, the few targets identified for cyanobacterial peptides in parasites are intracellular. Some cyanobacterial antiparasite peptides are active at picomolar concentrations, whereas those from higher eukaryotes usually work in the micromolar range. In all, cyanobacterial peptides are an appealing target to develop new antiparasite therapies and a challenge in the invention of new synthetic methods for peptides. This review aims to provide an updated appraisal of antiparasite cyanobacterial peptides and to establish a side-by –side comparison with those antiparasite peptides from higher eukaryotes., LR received economical support from grants from the Fondo de Investigaciones Sanitarias-ISCIII-FEDER [PI12-02706] and Red de Enfermedades Tropicales, subprogram RETICS-FEDER [RD16/0027/0010], and Plan Estatal de I + D + ii (2013–2016), co-financed with FEDER funds [SAF2015-65740-R], and a CSIC grant PIE [201620E038]. VR was financed by the Proyecto FONDECYT [1170379], CONICYT, Chile. We thank Felipe Pineda Rojas for its help in the design of the graphical abstract., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Structure-activity relationships and mechanistic studies of novel mitochondria-targeted, leishmanicidal derivatives of the 4-aminostyrylquinoline scaffold

  • Staderini, Matteo
  • Piquero, Marta
  • Abengozar, M. A.
  • Nácher-Vázquez, Montserrat
  • Romanelli, Giulia
  • López-Alvarado, Pilar
  • Rivas, Luis
  • Bolognesi, Maria Laura
  • Menéndez, J. Carlos
58 p.-6 fig.-1 tab.-5 schem.-1 graph.abst, A new class of quinoline derivatives, bearing amino chains at C-4 and a styryl group at C-2, were tested on Leishmania donovani promastigotes and axenic and intracellular Leishmania pifanoi amastigotes. The introduction of the C-4 substituent improves the activity, which is due to interference with the mitochondrial activity of the parasite and its concomitant bioenergetic collapse by ATP exhaustion. Some compounds show a promising antileishmanial profile, with low micromolar or submicromolar activity on promastigote and amastigote forms and a good selectivity index., This research was supported by the following grants; (a) MLB: MIUR, PRIN 201274BNKN_003; (b) JCM: Universidad Complutense (GR3/14) and MINECO (CTQ2015-68380-R); (c) LR: RD16/0027/0010, CSIC PIE-201020E054 and MINECO SAF2015-65740-R. A predoctoral contracts to MS from Universidad Complutense and a FPI contract to MP from MINECO (BES-2016–076410P) are also gratefully acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Imidazo[2,1-a]isoindole scaffold as an uncharted structure active on Leishmania donovani

  • Arsène, Sobinson
  • Gómez-Pérez, Veronica
  • Escarcena, Ricardo
  • Abengozar, M. A.
  • García-Hernández, Raquel
  • Nácher-Vázquez, Montserrat
  • San Feliciano, A.
  • Gamarro, Francisco
  • Rivas, Luis
  • del Olmo, Esther
35 p.-5 fig.-1 tab.-1 schem., The human protozoan parasites Leishmania donovani and L. infantum are the causative agents of visceral leishmaniasis, as such, responsible for approximately 30,000 deaths annually. The available chemotherapeutic treatments are reduced to a few drugs whose effectiveness is limited by rising drug resistance/therapeutic failure, and noxious side-effects. Therefore, new therapeutic hits are needed. Compounds displaying the imidazo[2,1-a]isoindole skeleton have shown antichagasic, anti-HIV, antimalarial and anorectic activities. Here, we report the leishmanicidal activity of thirty one imidazo[2,1-a]isoindol-5-ol derivatives on promastigotes and intracellular amastigotes of L. donovani. Eight out of thirty one assayed compounds showed EC50 values ranging between 1 and 2 μM with selectivity indexes from 29 to 69 on infected THP-1 cells. Six compounds were selected for further elucidation of their leishmanicidal mechanism. In this regard, compound 29, the imidazoisoindolol with the highest activity on intracellular amastigotes, induced an early decrease of intracellular ATP levels, as well as mitochondrial depolarization, together with a partial plasma membrane destructuration, as assessed by transmission electron microscopy. Consequently, the inhibition of the energy metabolism of Leishmania plays an important role in the leishmanicidal mechanism of this compound, even when other additional targets cannot be ruled out. In all, the results supported the inclusion of the imidazoisoindole scaffold for the development of new leishmanicidal drugs., Financial support from FIS-PI-060782, FIS-PI-052026, MINECO: RETOS (AGL2016-79813-C2-2, to EO), the Spanish Ministerio de Ciencia, Innovación y Universidades (RTI2018-097210-B-I00 to FG), ISCIII-RICET-FEDER: RD16/0027/0018 (EO) and RD16/0027/0010 (LR), and SAF2015-65740 (LR), as the CSIC grant PIE 201620E038 are acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3

  • Martínez de Iturrate, Paula
  • Sebastián-Pérez, Víctor
  • Nácher-Vázquez, Montserrat
  • Tremper, Catherine S.
  • Smirlis, Despina
  • Martín, Julio J.
  • Martínez Gil, Ana
  • Campillo, Nuria E.
  • Rivas, Luis
  • Gil, Carmen
13 p.-5 fig.-2 tab.-1 graph.abs + supp.inf. 38 p.-2 fig.supl.-5 tab. supl., Previous reports have validated the glycogen synthase kinase-3 (GSK-3) as a druggable target against the human protozoan parasite Leishmania. This prompted us to search for new leishmanicidal scaffolds as inhibitors of this enzyme from our in-house library of human GSK-3β inhibitors, as well as from the Leishbox collection of leishmanicidal compounds developed by GlaxoSmithKline. As a result, new leishmanicidal inhibitors acting on Leishmania GSK-3 at micromolar concentrations were found. These inhibitors belong to six different chemical classes (thiadiazolidindione, halomethylketone, maleimide, benzoimidazole, N-phenylpyrimidine-2-amine and oxadiazole). In addition, the binding mode of the most active compounds into Leishmania GSK-3 was approached using computational tools. On the whole, we have uncovered new chemical scaffolds with an appealing prospective in the development and use of Leishmania GSK-3 inhibitors against this infectious protozoan., Funding from MINECO [Grant SAF2015-65740-R], Instituto de Salud Carlos III RETICS programme RICET [RD16/0027/0010] with associated FEDER funds and MECD [Grant FPU15/1465 to V. S.-P.] is acknowledged. P. M. acknowledges the contract from the European Social Fund (Youth Employment Initiative) and FEDER funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Naphthoquinone as a New Chemical Scaffold for Leishmanicidal Inhibitors of Leishmania GSK-3

  • Sebastián-Pérez, Víctor
  • Martínez de Iturrate, Paula
  • Nácher-Vázquez, Montserrat
  • Nóvoa, Luis
  • Pérez, Concepción
  • Campillo, Nuria E.
  • Gil, Carmen
  • Rivas, Luis
More than 1 billion people live in areas endemic for leishmaniasis, which is a relevant threat for public health worldwide. Due to the inadequate treatments, there is an urgent need to develop novel alternative drugs and to validate new targets to fight this disease. One appealing approach is the selective inhibition of protein kinases (PKs), enzymes involved in a wide range of processes along the life cycle of Leishmania. Several PKs, including glycogen synthase kinase 3 (GSK-3), have been validated as essential for this parasite by genetic or pharmacological methods. Recently, novel chemical scaffolds have been uncovered as Leishmania GSK-3 inhibitors with antiparasitic activity. In order to find new inhibitors of this enzyme, a virtual screening of our in-house chemical library was carried out on the structure of the Leishmania GSK-3. The virtual hits identified were experimentally assayed both for leishmanicidal activity and for in vitro inhibition of the enzyme. The best hits have a quinone scaffold. Their optimization through a medicinal chemistry approach led to a set of new compounds, provided a frame to establish biochemical and antiparasitic structure–activity relationships, and delivered molecules with an improved selectivity index. Altogether, this study paves the way for a systemic search of this class of inhibitors for further development as potential leishmanicidal drugs., Funding from MINECO (Grant SAF2015-65740-R), Instituto de Salud Carlos III RETICS programme RICET (RD16/0027/0010) with associated FEDER funds and MECD (Grant FPU15/1465 to V.S.-P.) is acknowledged. P.M.I. acknowledges the contract from the European Social Fund (Youth Employment Initiative) and FEDER funds of the Autonomous Government of Madrid, Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Lytic cell death induced by melittin bypasses pyroptosis but induces NLRP3 inflammasome activation and IL-1β release

  • Martín-Sánchez, Fátima
  • Martínez-García, Juan José
  • Muñoz-García, María
  • Martínez-Villanueva, Miriam
  • Noguera-Velasco, José A.
  • Andreu Martínez, David
  • Rivas, Luis
  • Pelegrín, Pablo
The nucleotide-binding domain and leucine-rich repeat-containing receptor with a pyrin domain 3 (NLRP3) inflammasome is a sensor for different types of infections and alterations of homeostatic parameters, including abnormally high levels of the extracellular nucleotide ATP or crystallization of different metabolites. All NLRP3 activators trigger a similar intracellular pathway, where a decrease in intracellular K+ concentration and permeabilization of plasma membrane are key steps. Cationic amphipathic antimicrobial peptides and peptide toxins permeabilize the plasma membrane. In fact, some of them have been described to activate the NLRP3 inflammasome. Among them, the bee venom antimicrobial toxin peptide melittin is known to elicit an inflammatory reaction via the NLRP3 inflammasome in response to bee venom. Our study found that melittin induces canonical NLRP3 inflammasome activation by plasma membrane permeabilization and a reduction in the intracellular K+ concentration. Following melittin treatment, the apoptosis-associated speck-like protein, an adaptor protein with a caspase recruitment domain (ASC), was necessary to activate caspase-1 and induce IL-1β release. However, cell death induced by melittin prevented the formation of large ASC aggregates, amplification of caspase-1 activation, IL-18 release and execution of pyroptosis. Therefore, melittin-induced activation of the NLRP3 inflammasome results in an attenuated inflammasome response that does not result in caspase-1 dependent cell death., This work was supported by SAF2015-65740-R and Subdirección General de Redes y Centros de Investigación Cooperativa-FEDER, RICET RD12/0018/0007 and RD16/0027/0010. This work was also supported by grants from the European Research Council (ERC-2013-CoG 614578 to PP) and the Instituto Salud Carlos III-Fondo Europeo de Desarrollo Regional (PI13/00174 to PP). FM-S was supported by the Sara Borrell postdoctoral grant from the Instituto Salud Carlos III (CD12/00523)